The studies
Ipamorelin research, study by study — newest data first
Mechanism, the human pharmacokinetics, the one failed human trial, and the freshest 2024–2026 work, each carried back to its source.
The short version
Ipamorelin research is wide on mechanism and narrow on human outcomes. The founding study showed it releases growth hormone cleanly — strong pulse, little cortisol or prolactin [1]. A human pharmacology study pinned its half-life near two hours [2]. The one mid-stage human trial, for slow bowel recovery after surgery, did not beat placebo [3]. Animal work fills in the rest: dose-dependent bone growth in rats [4], a 2024 ferret study where it cut chemotherapy weight loss by about a quarter [5], and a direct effect on the pancreas [11]. The newest 2026 reviews call it promising in animals and unproven in people [14][15][16][17]. This page walks each of those, newest first.
The newest data: a 2024 cachexia result and 2026 reviews
The freshest in-vivo study is from 2024. In a ferret model of cisplatin chemotherapy, intraperitoneal ipamorelin at 1–3 mg/kg inhibited body-weight loss by about 24% on the last day of the delayed phase (48–72 h) — but had no anti-emetic effect on either acute or delayed emesis, in contrast to central anamorelin, which cut acute emesis by 60% [5]. The takeaway is mechanistic: ipamorelin's weight-protective effect here is peripheral, not a nausea fix.
The 2026 review wave is unanimous on the evidence ceiling. An orthopaedic narrative review found CJC-1295 plus ipamorelin improved maximum tetanic tension in a glucocorticoid muscle-loss model in mice while flagging that the evidence is animal-only [14]. A sports-medicine review classified ipamorelin as an investigational growth-hormone-axis peptide with no reproducible human musculoskeletal evidence and urged confining use to research protocols [17]. A broader sports-medicine safety-and-efficacy review reached the same place and emphasized the potential for serious harm [15]; a metabolic/endocrine therapeutic-peptide review placed ipamorelin among unapproved compounds needing human study before safe use [16].
Mechanism: GHS-R1a selectivity
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a selective agonist of GHS-R1a, the ghrelin receptor, on pituitary somatotrophs (the growth-hormone-secreting cells). Binding triggers a Gq/phospholipase-C cascade, intracellular calcium rises, and growth hormone is released as a discrete pulse [1]. The defining result: in rat pituitary cells, rats, and swine, ipamorelin matched GHRP-6's growth-hormone potency (swine ED50 = 2.3 nmol/kg) yet left ACTH and cortisol at GHRH-equivalent levels even above 200× its growth-hormone ED50 [1]. It releases growth hormone by a route distinct from GHRH, which is the mechanistic basis for combining it with GHRH analogs.
Its reach is not limited to the pituitary. Ex-vivo rat pancreatic tissue released insulin directly in response to ipamorelin, an effect blunted by L-type calcium-channel, α2-adrenergic, and cholinergic blockade — a peripheral, growth-hormone-independent action [11]. Glucocorticoids do not shut the pathway down: methylprednisolone (5.0 mg/kg/day for 8 days) did not blunt the acute growth-hormone response in rats, and the combination raised IGF-1 and improved body-weight recovery versus steroid alone [8].
What is cjc 1295 ipamorelin
What is cjc 1295 ipamorelin: it is a pairing of two different growth-hormone secretagogues, not a single molecule. CJC-1295 is a GHRH analog that works through the GHRH receptor; ipamorelin is a ghrelin-receptor (GHS-R1a) agonist [1]. Because they act through separate receptors, their growth-hormone-releasing effects are mechanistically complementary — the rationale for using them together. A 2026 orthopaedic review reported the pair improved maximum tetanic tension in a glucocorticoid muscle-loss model in mice, while stressing the evidence is animal-only [14]. No human trial has tested the combination for any outcome.
Ipamorelin cjc-1295
The ipamorelin cjc-1295 combination is the single most-searched ipamorelin topic, and the evidence is entirely preclinical. The case for it is pharmacological: a GHRH analog (CJC-1295) and a ghrelin-receptor agonist (ipamorelin) push growth-hormone release through two different pathways that add together rather than overlap [1]. The strongest recent data point is a 2026 narrative review reporting improved maximum tetanic tension in a murine glucocorticoid-induced muscle-loss model with the combination [14]. But that is a mouse result inside a review, not a controlled human trial — and the combination has no published human efficacy or safety study of its own. Treating it as established human therapy outruns the data.
Bone, body composition, and the medicinal-chemistry legacy
In adult female rats, subcutaneous ipamorelin at 18, 90, and 450 µg/day (divided three times daily for 15 days) raised the longitudinal bone-growth rate dose-dependently from 42 µm/day (vehicle) to 44, 50, and 52 µm/day — with no change in total IGF-1, IGF-binding proteins, or bone-turnover markers [4]. The skeletal effect appears partly local and pulse-driven rather than IGF-1-mediated. Large-animal work in swine confirmed the GH-selective profile that distinguishes ipamorelin from earlier GHRPs [10].
Ipamorelin also seeded medicinal chemistry. A peptidomimetic series built on its scaffold reached comparable in-vivo potency (≈2 nmol/kg IV in swine) while achieving roughly 10% oral bioavailability in dogs [9] — showing the pharmacophore could be pushed toward orally active secretagogues, even though ipamorelin itself is not orally bioavailable. The ghrelin system the compound targets is itself implicated in aging muscle: a 2024 study found unacylated ghrelin protected against age-related loss of muscle mass and contractile dysfunction [7] (the tested agent was ghrelin, not ipamorelin).
Does cjc-1295 ipamorelin work
Does cjc-1295 ipamorelin work depends on the standard of proof. In animal models, yes in a narrow sense — a 2026 review reported improved maximum tetanic tension in a murine glucocorticoid muscle-loss model [14], and single-agent rodent studies show real growth-hormone release [1] and bone growth [4]. In controlled human outcome terms, there is no evidence either way: no human trial has tested the combination, and ipamorelin's lone human efficacy trial (for postoperative ileus) missed its primary endpoint [3]. So the combination 'works' as pharmacology and in animals; it is unproven as a human therapy.
Is ipamorelin fda approved
Is ipamorelin fda approved: no. Ipamorelin has never been approved as a drug by the FDA or any other regulatory authority, for any indication [3]. It was investigated for postoperative ileus (NCT00672074), but that Phase 2 trial missed its primary endpoint and no further clinical development followed [3]. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk-substances list and reviewed it at the October 29, 2024 Pharmacy Compounding Advisory Committee meeting, restricting compounding-pharmacy access. It is also prohibited in sport at all times under WADA category S2. Available material is sold strictly as a research chemical.